

## Elekta Esprit receives Red Dot design award for its focus on patients and clinicians

*Elekta's latest Leksell Gamma Knife® stereotactic radiosurgery (SRS) system, Esprit, wins Red Dot Award*

STOCKHOLM – Elekta (EKTA-B.ST) Esprit, a high precision stereotactic radiosurgery device, used to treat targets in the brain, such as tumors, vascular malformations, or functional disorders, has been awarded the Red Dot Award for product design in the medical devices and technology design category. By combining form and function in an exquisite manner, Elekta Esprit has received an internationally renowned winner label of the highest reputation.

According to the Red Dot organization, its award represents global recognition of belonging to the best in design and business and the [Red Dot Design Award](#) competition has been held since 1955. The jury, comprising some 50 international experts, tests, discusses and evaluates each entry individually.

This latest incarnation of the trusted Leksell Gamma Knife offers more efficient and seamless workflows with a modern aesthetic and a clean, light and friendly expression. Moreover, Elekta Esprit emphasizes simple, minimalist design language that shifts the focus away from the machine and celebrates Elekta's emphasis on the user and patient experience of the system.

Susanna Francke Rodau, Senior VP & Head of Neuro Solutions, said: "The experience of the user and the patient is at the heart of this innovation, where design and function have been combined in a holistic, seamlessly integrated package. Although Esprit is technically complex, it is an easy-to-use solution capable of treating very challenging indications and provides life-changing results for patients."

Elekta Esprit offers more personalized and patient-friendly treatments, and a degree of precision able to protect the mind and the person.

For more information, visit [www.elekta.com/elekta-esprit](http://www.elekta.com/elekta-esprit)

*Elekta Esprit is CE marked and FDA 510(k) cleared, with limited global availability.*

###

### **For further information, please contact:**

Mattias Thorsson, Vice President, Head of Corporate Communications

Tel: +46 70 865 8012, e-mail: [Mattias.Thorsson@elekta.com](mailto:Mattias.Thorsson@elekta.com)

Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations

Tel: +1 770-670-2524, e-mail: [Raven.Canzeri@elekta.com](mailto:Raven.Canzeri@elekta.com)

Time zone: ET: Eastern Time



---

### **About Elekta**

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit [elekta.com](https://www.elekta.com) or follow [@Elekta](https://twitter.com/Elekta) on Twitter.